Telomerase is an enzyme whose primary job is to rebuild the protective caps on the ends of your chromosomes, called telomeres, so they do not shorten every time a cell divides. Without telomerase, each round of cell division chips away at these caps until the cell can no longer replicate. The enzyme is one of the most studied molecules in aging and cancer biology, and for good reason: its presence or absence in a given cell can mean the difference between renewal and decline, or between normal tissue and a tumor. But the full picture of what telomerase does, and does not do, is richer and stranger than that summary suggests.
How Telomerase Adds DNA to Chromosome Ends
Every chromosome ends in a stretch of repetitive DNA sequences that act like the plastic tips on shoelaces. In humans, the repeating unit is six letters long (TTAGGG), and these repeats can run for thousands of base pairs. Normal DNA replication cannot copy the very tip of a chromosome, so a small piece gets lost each time a cell divides. Left unchecked, this erosion eventually eats into genes that the cell actually needs, triggering either cell death or a permanent growth arrest called senescence.
Telomerase solves this by carrying its own RNA template, a short sequence that it uses as a guide to add new telomeric repeats onto the chromosome’s exposed end. It is, in essence, a specialized reverse transcriptase: it reads RNA and writes DNA, the opposite of the usual transcription process. The enzyme’s RNA subunit contains the template, and its protein subunit (called TERT) does the actual synthesis work, stitching new TTAGGG repeats onto the 3′ end of the chromosome one at a time.1PubMed Central. Telomerase repeat addition processivity is increased at critically short telomeres in a Tel1-dependent manner in Saccharomyces cerevisiae
A high-resolution structure of the human telomerase complex, obtained through cryo-electron microscopy, revealed that the enzyme consists of two lobes connected by a flexible RNA tether. One lobe is the catalytic core where TERT and the RNA template do their work; the other is a protein complex involved in the enzyme’s stability and localization within the cell. The RNA wraps around TERT in a well-organized structure, though the protein and RNA make surprisingly few direct contacts considering how tightly they work together.2PubMed Central. Cryo-EM structure of substrate-bound human telomerase holoenzyme
An important detail about how telomerase works is its “processivity,” a term describing how many repeats the enzyme adds during a single visit to a chromosome end. Under normal conditions, telomerase in yeast is not very processive: it adds a few repeats and falls off. But when a telomere gets critically short, the enzyme ramps up its activity dramatically, adding many more repeats per visit. This burst of activity at the shortest telomeres acts as an emergency repair mechanism, preferentially rescuing the most vulnerable chromosome ends.3PubMed Central. Telomerase repeat addition processivity is increased at critically short telomeres in a Tel1-dependent manner in Saccharomyces cerevisiae
How Telomerase Reaches Its Target
Making telomeric DNA is only half the job. The enzyme also has to find the right chromosome ends and arrive at the right time. Telomerase does not sit at telomeres around the clock. Instead, it is recruited during a specific window of the cell cycle, primarily during S phase, when the cell is copying its DNA. Both the RNA and protein components of telomerase travel through nuclear structures called Cajal bodies before being delivered to telomeres.4PubMed Central. Cell cycle-regulated trafficking of human telomerase to telomeres
Cajal bodies are small, dynamic compartments inside the nucleus that appear to serve as assembly and staging areas for telomerase. Time-lapse imaging of cancer cells shows Cajal bodies drifting through the nucleus and pausing at telomeres for about 10 to 40 minutes during S phase, potentially delivering telomerase RNA to the chromosome ends that need extension.5PubMed Central. Cell cycle-dependent recruitment of telomerase RNA and Cajal bodies to human telomeres A protein called TCAB1, part of the telomerase holoenzyme, is essential for concentrating telomerase inside Cajal bodies; when TCAB1 is depleted, telomerase cannot reach telomeres efficiently.6PubMed Central. Telomerase Cajal body protein 1 depletion inhibits telomerase trafficking to telomeres and induces G(1) cell cycle arrest in A549 cells
Once at the telomere, telomerase must interact with a protein complex called shelterin, which normally coats and protects the chromosome tip. One shelterin component, TPP1, plays a crucial role in physically recruiting telomerase. Experiments using gene editing to remove TPP1 completely abolished telomerase activity at telomeres. Interestingly, another shelterin component, POT1, turns out to be dispensable for recruitment: cells missing POT1 showed no measurable loss of telomerase activity, suggesting that different parts of the protective complex have sharply different roles in bringing the enzyme to its target.7Nature Communications. Control of telomerase recruitment and end protection by independent shelterin components
Where Telomerase Is and Is Not Active
One of the most consequential things about telomerase is that most of your cells do not express it. During early fetal development, telomerase is active across essentially all tissues. But as an embryo grows, different organs shut down the enzyme on different schedules. A study of human fetal tissues from 8 to 21 weeks of gestation found that heart tissue lost detectable telomerase activity by the 12th week, brain and kidney by the 16th week, while lung, liver, spleen, and testis maintained it through at least 21 weeks.8Molecular Human Reproduction. Developmental regulation of telomerase activity in human fetal tissues during gestation The shutdown is not caused by an inhibitor blocking the enzyme; those tissues simply stop producing active telomerase.
The silencing of the TERT gene, which codes for telomerase’s protein component, involves specific chemical modifications to the surrounding DNA. As embryonic stem cells differentiate into adult cell types, the TERT promoter accumulates repressive marks that physically prevent the gene from being read. This process is driven by the genomic context around the human TERT gene, meaning the DNA neighborhood itself determines how thoroughly the gene gets locked down.9Scientific Reports. Regulation of human and mouse telomerase genes by genomic contexts and transcription factors during embryonic stem cell differentiation
In adults, telomerase remains active mainly in cells that need to keep dividing: stem cells in the bone marrow, skin, gut lining, and immune system, as well as germ cells in the reproductive organs. Even in these populations, telomerase activity is modest compared to what embryonic cells produce. This matters because the gradual shortening of telomeres in stem cell compartments can exhaust the regenerative capacity of organs over decades, contributing to age-related decline.10PubMed Central. Telomeres and Telomerase in the Control of Stem Cells Telomere loss does not just count down passively. When telomeres reach a critically short threshold, they trigger a cell-cycle checkpoint involving the tumor suppressor p53, which forces the cell to stop dividing permanently.11PubMed. Telomeres: influencing the rate of aging
Telomerase and Cancer
The same telomere-shortening mechanism that drives aging also serves as a natural brake on cancer. A cell that cannot maintain its telomeres will eventually hit a wall and stop dividing, which is exactly what you want from a rogue cell trying to grow into a tumor. Cancer cells get around this by reactivating telomerase. Roughly 85 to 90 percent of human cancers show telomerase activity, making it one of the most common features of malignancy.
One of the most studied ways cancers flip telomerase back on involves mutations in the TERT gene’s promoter, the stretch of DNA that controls when and how much TERT gets produced. These point mutations create new binding sites for transcription factors called ETS proteins, which ramp up TERT production. The mutations show up at high frequency in melanoma, glioma, liver cancer, bladder cancer, and several other tumor types, and they tend to mark patients with worse outcomes.12PubMed. TERT promoter mutations in telomere biology In bladder cancer cell lines, these promoter mutations correlate with higher TERT protein levels, greater telomerase enzyme activity, and longer telomeres compared to cells without the mutations.13PubMed Central. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer
Beyond mutations, the regulation of TERT in cancer also involves epigenetic mechanisms, particularly DNA methylation. Changes in the methylation pattern of the TERT promoter can open up the surrounding DNA, making it accessible to the cellular machinery that reads genes. In one set of experiments on eye melanoma cell lines, higher methylation at a specific site near the TERT promoter correlated strongly with more open chromatin and higher TERT expression.14PLOS ONE. Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression This interplay between mutations and methylation gives cancers multiple overlapping routes to switch telomerase on and keep it running.
When Cancer Skips Telomerase Entirely
Not every cancer relies on telomerase. About 10 to 15 percent of tumors use a different strategy called alternative lengthening of telomeres, or ALT, which bypasses the enzyme altogether. Instead of using an RNA template, ALT cells extend their telomeres through DNA repair pathways that copy one telomere’s sequence onto another. The process hijacks homology-directed repair, a mechanism cells normally use to fix broken DNA, and repurposes it for telomere maintenance.15PubMed Central. Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends
ALT tends to appear in some of the most treatment-resistant cancer subtypes, including certain brain tumors, bone cancers, and soft tissue sarcomas. The telomeres in ALT cells look distinctly different from normal telomeres: they are highly variable in length and show signs of ongoing DNA damage and replication stress that continuously feed the repair cycle.16Journal of Clinical Pathology. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer The existence of ALT is one of the reasons why a drug targeting telomerase alone would not cure all cancers. Any surviving cancer cell that switches to ALT could repopulate the tumor.
What Happens When Telomerase Is Defective
If too much telomerase fuels cancer, too little causes a different set of problems. Inherited mutations in the genes encoding TERT or its RNA component (TERC) cause a family of diseases collectively called telomeropathies. The most recognized is dyskeratosis congenita, a syndrome characterized by abnormal skin pigmentation, nail dystrophy, and white patches in the mouth, along with bone marrow failure. But the spectrum extends further: some cases of idiopathic pulmonary fibrosis, a progressive scarring of the lungs, are also driven by telomerase mutations.17PLoS ONE. Telomere Lengths, Pulmonary Fibrosis and Telomerase (TERT) Mutations
Laboratory studies of cells carrying these mutations have shown that the damage goes beyond simple telomere shortening. Mutant TERT and TERC also trigger increased oxidative stress, DNA damage at telomeres, reduced recruitment of protective shelterin proteins, and higher rates of programmed cell death. These effects suggest that telomerase mutations harm cells through multiple pathways at once, not just by failing to maintain telomere length.18PubMed Central. Clinical mutations in the TERT and TERC genes coding for telomerase components induced oxidative stress, DNA damage at telomeres and cell apoptosis besides decreased telomerase activity
Beyond Telomeres: Telomerase’s Other Jobs
The discovery that TERT has functions beyond extending telomeres was one of the genuine surprises in the field. The protein shows up inside mitochondria, the cell’s energy-producing compartments, where it protects mitochondrial DNA and helps maintain antioxidant enzyme levels. TERT also influences the cellular balance of reactive oxygen species, acting as both a responder to oxidative stress and a regulator of it.19PubMed Central. Non-canonical functions of Telomerase Reverse Transcriptase – Impact on redox homeostasis
These “extra-telomeric” roles extend even further. TERT participates in modifying chromatin structure, influencing which genes get turned on or off. It has been linked to regulating blood vessel formation and metabolic processes including glucose handling and mitochondrial function.20PubMed Central. Canonical and extra-telomeric functions of telomerase: Implications for healthy ageing conferred by endurance training This means that when researchers boost or block telomerase experimentally, they are not just changing telomere length. They are also tweaking a web of cellular processes, which complicates both anti-aging and anti-cancer applications.
Therapeutic Efforts Targeting Telomerase
Given that most cancers depend on telomerase, the enzyme has long been an attractive drug target. The most advanced telomerase inhibitor to reach the clinic is imetelstat, a modified piece of synthetic DNA that binds to the RNA template of telomerase and blocks it. Imetelstat was approved in the United States in June 2024 for a specific blood disorder: lower-risk myelodysplastic syndromes with transfusion-dependent anemia. In its pivotal trial, significantly more patients treated with imetelstat achieved sustained independence from blood transfusions compared to placebo.21PubMed Central. Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science
In solid tumors, results have been more mixed. A randomized trial in advanced non-small-cell lung cancer found no significant improvement in progression-free survival with imetelstat maintenance therapy. There was a trend toward longer overall survival (about 14 months versus 11.5 months), but it did not reach statistical significance. An exploratory analysis hinted that patients whose tumors had short telomeres at baseline might benefit more, which makes biological sense: those tumors would be most dependent on telomerase to keep growing.22PubMed Central. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer In myelofibrosis, a pilot study showed that about a fifth of patients achieved a complete or partial response, with bone marrow scarring actually reversing in those with the best responses.23PubMed. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
On the opposite end of the spectrum, some researchers are trying to boost telomerase to combat aging. In mice, delivering the TERT gene via a virus-based vector to one-year-old and two-year-old animals improved insulin sensitivity, bone density, neuromuscular coordination, and several molecular markers of aging. The treated mice lived about 24 percent longer when treated at age one and 13 percent longer when treated at age two. Crucially, the treated mice did not develop more tumors than untreated animals, suggesting that delivering telomerase to already-adult organisms may carry less cancer risk than having it turned on constitutively from birth.24PubMed Central. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer Similar gene therapy in a mouse model of Hutchinson-Gilford progeria, a disease of accelerated aging, extended lifespan by about 20 percent and reduced levels of the toxic protein progerin.25European Heart Journal. Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice
Supplements Claiming to Activate Telomerase
A commercially available supplement called TA-65, derived from the herb Astragalus membranaceus, has been marketed as a telomerase activator for over a decade. A randomized, placebo-controlled trial reported that subjects taking the low dose showed a statistically significant increase in telomere length over 12 months, while the placebo group lost telomere length over the same period.26PubMed Central. A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study However, a recent systematic review and meta-analysis found that while TA-65 produced a moderate increase in telomere length across studies, this effect did not translate into improvements in frailty or inflammation. The review also noted that industry-funded trials reported larger effects than independent ones, and it described the gap between telomere elongation and any real functional benefit as a “telomere-function disconnect.”27PubMed Central. Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis
This disconnect is worth pausing on. Making telomeres measurably longer in a blood test is not the same as making a person healthier or younger in any meaningful sense. Telomere length is influenced by many factors and is a rough correlate of cellular aging, not a direct dial you can turn. Until supplements can demonstrate concrete health improvements in well-designed trials, their value remains unproven.
Lifestyle Factors and Telomerase Activity
Beyond pills, everyday habits appear to influence telomerase activity in measurable ways. A systematic review of human studies found that chronic psychological stress was consistently associated with lower telomerase activity, while lifestyle interventions including exercise, dietary micronutrient supplementation, and meditation practices were linked to increases in telomerase activity in the majority of studies examined.28PubMed. Telomerase activity and its association with psychological stress, mental disorders, lifestyle factors and interventions: A systematic review A pilot study of comprehensive lifestyle changes (plant-based diet, moderate exercise, stress management, and social support) in men found that telomerase activity in immune cells increased after three months, and that the gains were correlated with reductions in LDL cholesterol and psychological distress.29The Lancet Oncology. Increased telomerase activity and comprehensive lifestyle changes: a pilot study
These are encouraging associations, but they come with the usual caveats of observational and small-sample research. Nobody can say yet whether the telomerase increases caused the health improvements, or whether both were downstream effects of the lifestyle changes themselves. Still, the consistent direction of the findings across multiple study types suggests that the everyday environment of your cells matters for telomerase function, not just your genetic blueprint.
Why Larger Animals Suppress Telomerase
One of the more illuminating perspectives on telomerase comes from comparative biology. You might expect that long-lived species would maintain high telomerase activity to keep their telomeres in good shape. The data say otherwise. In a study of 15 rodent species with widely varying lifespans and body sizes, telomerase activity did not co-evolve with lifespan. Instead, it co-evolved with body mass: larger rodents suppress telomerase in their somatic tissues, while smaller ones keep it active.30PubMed Central. Telomerase activity coevolves with body mass not lifespan
The leading explanation is that large body size, not long life, presents the greater cancer risk. A bigger animal has more cells, each of which could potentially become malignant. Shutting down telomerase in somatic tissues acts as a cancer-prevention strategy, limiting how many times any given cell can divide. Long-lived species appear to have evolved other, separate tumor-suppression mechanisms that do not rely on telomere shortening alone.31PubMed Central. Distinct tumor suppressor mechanisms evolve in rodent species that differ in size and lifespan Meanwhile, telomere length itself, rather than telomerase activity, does show an independent association with lifespan across a broader sample of mammals, suggesting the two variables are uncoupled in evolution and serve different biological purposes.32PubMed Central. Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination
An Ancient Enzyme with a Retrotransposon Past
Telomerase exists across nearly all eukaryotic life, from single-celled protists to plants to humans. Where did it come from? Sequence comparisons of the TERT protein with other known reverse transcriptases point to an origin among ancient mobile genetic elements called retrotransposons, specifically a class known as non-LTR retrotransposons. Both telomerase and these elements use the same basic strategy: they read an RNA template and write DNA, using the chromosome itself as a primer. The key difference is that retrotransposons carry an endonuclease domain that lets them insert copies of themselves throughout the genome, while TERT lacks this domain, restricting it to the chromosome ends. A group of retrotransposons called Penelope-like elements shares especially close sequence similarity with TERT and also targets chromosome termini, leading to the hypothesis that an ancestor of modern TERT was a retrotransposon that lost its ability to insert elsewhere and became domesticated as a telomere-maintenance enzyme.
Measuring Telomerase in the Lab and Clinic
Detecting telomerase activity is important for cancer diagnostics, telomeropathy screening, and aging research. The standard method since 1994 has been the telomerase repeat amplification protocol, or TRAP, which lets telomerase extend a synthetic DNA primer in a test tube and then amplifies the products for detection. Since then, the basic TRAP assay has been adapted into dozens of variants including real-time amplification, isothermal amplification, and newer approaches using nanotechnology and gene-editing tools.33PubMed. Measuring telomerase activity using TRAP assays
One of the more striking recent advances uses droplet digital PCR to measure telomerase activity in individual cells. When researchers applied this technique to HeLa cancer cells, they found that about 73 percent of individual cells showed detectable telomerase activity, while the remaining roughly 27 percent did not, suggesting that even within a cancer cell line known for its telomerase expression, activity is not uniform from cell to cell.34Nucleic Acids Research. Quantitative telomerase enzyme activity determination using droplet digital PCR with single cell resolution That kind of single-cell resolution is important because average measurements across millions of cells can mask biologically meaningful variation, which matters both for understanding tumor biology and for evaluating whether a drug is actually shutting down telomerase in the cells that need it blocked most.